Fig. 4
Enhanced iv LV-mWasabi gene transfer in mice after non-myeloablative immune suppression. A Illustration of tail vein injection of LV-mWasabi into WT mice and LV-F8BDD into F8null mice pretreated with non-myeloablative radiation (6 Gy). The WT mice received tail vein iv injection of LV-mWasabi under the different promoters, EF1α, VEC, Gp and ITGA, at 1 × 107 TU per mouse or 100 μL PBS per mouse as mock control. The blood was collected on Day 7, 15, 30, 45, 60, 120 and 180 after injection. B–D LV-GFP expression analysis by flow cytometry in BM, liver and spleen on day 30. The BM cells (B) were analyzed using antibodies for the different lineage-specific markers including CD34 for hematopoietic stem/progenitor cells, CD11b for monocytes/macrophages or DCs, Ly-6G for granulocytes and F4/80 for mature macrophages. In addition, the BM, liver (C) and spleen cells (D) were analyzed using Abs to CD41, a megakaryotic marker and CD31, an early endothelial marker